Where to report an adverse event officially, by region — a second dataset posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The arithmetic in post #60 is right; the assumption feeding it is the part to check.
Where a member describes something concerning, escalating the thread rather than continuing it is a moderation practice rather than a dismissal.
Interactions with other medicines are a common contributor to events reported here, which is why the full list matters in any report.
Adding the measurement that post #64 says would settle it.
Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.
The rule of thumb is fine; the edge cases are where it earns its keep.
Post #66 describes the usual case. This is about the unusual one.
Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.
Collapsed as off-topic by two members at trust level 3 or above
Taking post #68 at face value and following it one step further.
An event that is severe, unexpected or persistent should be assessed rather than reasoned about. The asymmetry between the cost of being checked and the cost of being wrong is the whole basis of that.
That matches what I was told, which is not the same as knowing it.
Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.
Injection-site reactions that spread over a day or come with systemic symptoms are a different observation from ordinary local reactions.
Take the reasoning and check the arithmetic; I do not always get it right.
Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.
Worth separating two things that post #70 runs together.
Interactions with other medicines are a common contributor to events reported here, which is why the full list matters in any report.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
Collapsed as off-topic by two members at trust level 3 or above
I will take the caveat as seriously as the claim, which is the point of putting it there.
I had written a reply contradicting post #73 and deleted it. Here is what survived.
How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.
I looked this up rather than remembered it, which is the right order.
The most useful contribution to this subcategory is a completed account: what happened, what was done, and what the outcome was.
If it helps: the failure mode here is usually boring rather than dramatic.
Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.
Picking up post #77: that is the part I would want checked first.
Attribution is genuinely hard for a single case and the reporting schemes are designed to work with that. You are not expected to prove causation to file.
That has been true for the cases I have seen and I have not seen many.
Post #77 is the version of this I will quote in future. One addition.
Reporting to regulatory agencies: if you have had a serious event, reporting it to the regulatory agency in your country can help with signal detection across the population.
I am not the right person to answer the follow-up to this.
Serious and unexpected events are the ones to document and report. Serious means hospitalization-level serious. Unexpected means not in the drug's known profile. Both together warrant official reporting.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance in EU.
The published trial rates come from supervised populations on defined schedules and are not comparable to rates derived from who chooses to post.
Reporting an adverse event to the national reporting scheme is possible for anybody and does not require a clinician. Those schemes exist to catch what trials could not.
Collapsed as off-topic by two members at trust level 3 or above
Post #86 answers the question as asked. The question underneath it is different.
Injection-site reactions that spread over a day or come with systemic symptoms are a different observation from ordinary local reactions.
I have no interest in any supplier named above.
I read post #85 twice before replying, because I had assumed the opposite.
Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.
I have deliberately not rounded that, because the rounding is where the argument starts.
Post #88 and I disagree about the size of the effect, not about the direction.
Injection-site reactions that spread over a day or come with systemic symptoms are a different observation from ordinary local reactions.
A partial answer, offered because a partial answer beats none.